Loading...
XNASIRWD
Market cap584mUSD
Jan 14, Last price  
3.65USD
1D
-3.18%
1Q
-18.89%
Jan 2017
-76.13%
IPO
-68.59%
Name

Ironwood Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:IRWD chart
P/E
P/S
1.32
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
0.36%
Rev. gr., 5y
5.02%
Revenues
443m
+7.83%
10,464,00022,216,00036,102,00043,857,00065,871,000150,245,00022,881,00076,436,000149,555,000273,957,000298,276,000346,639,000428,413,000389,523,000413,753,000410,596,000442,735,000
Net income
-1.00b
L
-52,752,000-53,874,000-71,185,000-52,981,000-64,852,000-72,624,000-272,812,000-189,618,000-142,669,000-81,708,000-116,937,000-282,368,000-15,314,000106,176,000528,448,000175,065,000-1,002,239,000
CFO
183m
-33.00%
-6,759,000-28,195,000-3,998,000-67,899,000-75,237,000-69,633,000-273,355,000-155,568,000-106,927,000-25,433,000-99,563,000-70,882,00010,725,000168,836,000261,895,000273,763,000183,427,000
Earnings
Feb 13, 2025

Profile

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
IPO date
Feb 03, 2010
Employees
219
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
442,735
7.83%
410,596
-0.76%
Cost of revenue
117,660
45,683
Unusual Expense (Income)
NOPBT
325,075
364,913
NOPBT Margin
73.42%
88.87%
Operating Taxes
83,490
77,357
Tax Rate
25.68%
21.20%
NOPAT
241,585
287,556
Net income
(1,002,239)
-672.50%
175,065
-66.87%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,357
(116,854)
BB yield
-0.36%
5.06%
Debt
Debt current
202,686
3,065
Long-term debt
530,521
432,514
Deferred revenue
Other long-term liabilities
28,415
9,766
Net debt
641,053
(235,698)
Cash flow
Cash from operating activities
183,427
273,763
CAPEX
(273)
(136)
Cash from investing activities
(1,026,318)
(136)
Cash from financing activities
277,160
(237,553)
FCF
276,725
271,590
Balance
Cash
92,154
656,203
Long term investments
15,074
Excess cash
70,017
650,747
Stockholders' equity
(1,701,490)
(696,222)
Invested Capital
2,099,148
1,773,625
ROIC
12.48%
15.15%
ROCE
81.75%
33.87%
EV
Common stock shares outstanding
155,435
186,312
Price
11.44
-7.67%
12.39
6.26%
Market cap
1,778,176
-22.97%
2,308,406
20.41%
EV
2,419,229
2,072,708
EBITDA
326,650
366,331
EV/EBITDA
7.41
5.66
Interest
21,629
7,598
Interest/NOPBT
6.65%
2.08%